Tenascin-C and fibronectin expression divide early stage tongue cancer into low- and high-risk groups by Sundquist, Elias et al.
Tenascin-C and fibronectin expression divide
early stage tongue cancer into low- and
high-risk groups
Elias Sundquist*,1,2, Joonas H Kauppila1,2,3, Johanna Veijola4,5, Rayan Mroueh6, Petri Lehenkari1,2,
Saara Laitinen7, Juha Risteli2,8,9, Ylermi Soini10,11, Veli-Matti Kosma10,11,12, Iris Sawazaki-Calone13,
Carolina Carneiro Soares Macedo14, Risto Bloigu15, Ricardo D Coletta14 and Tuula Salo1,2,16
1Cancer and Translational Medicine Research Unit, University of Oulu, Oulu FI-90014, Finland; 2Medical Research Centre, Oulu
University Hospital, Oulu FI-90014, Finland; 3Department of Molecular Medicine and Surgery, Upper Gastrointestinal Surgery,
Karolinska Institutet, Karolinska University Hospital, Stockholm 17176, Sweden; 4Department of Physiology, Institute of
Biomedicine, University of Oulu, Oulu FI-90014, Finland; 5Department of Biochemistry and Molecular Medicine, University of
Oulu and Biocenter Oulu, Oulu FI-90014, Finland; 6Department of Otorhinolaryngology—Head and Neck Surgery, University of
Helsinki and Helsinki University Hospital, Helsinki FI-00014, Finland; 7Department of Research and Development, Finnish Red
Cross Blood Service, Helsinki FI-00014, Finland; 8Department of Clinical Chemistry, Institute of Diagnostics, University of Oulu,
Oulu FI-90014, Finland; 9Northern Laboratory Centre NordLab, Oulu FI-90220, Finland; 10Department of Clinical Pathology and
Forensic Medicine, University of Eastern Finland, Kuopio FI-70211, Finland; 11Cancer Centre of Eastern Finland and Kuopio
University Hospital, Kuopio FI-70210, Finland; 12Department of Clinical Pathology, Imaging Centre, Kuopio University Hospital,
Kuopio FI-70211, Finland; 13Oral Pathology and Oral Medicine, Dentistry School, Western Paraná State University, Cascavel 85819-
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Background: Oral tongue squamous cell carcinoma (OTSCC) metastasises early, especially to regional lymph nodes. There is an
ongoing debate on which early stage (T1-T2N0) patients should be treated with elective neck dissection. We need
prognosticators for early stage tongue cancer.
Methods: Mice immunisation with human mesenchymal stromal cells resulted in production of antibodies against tenascin-C
(TNC) and fibronectin (FN), which were used to stain 178 (98 early stage), oral tongue squamous cell carcinoma samples. Tenascin-
C and FN expression in the stroma (negative, moderate or abundant) and tumour cells (negative or positive) were assessed. Similar
staining was obtained using corresponding commercial antibodies.
Results: Expression of TNC and FN in the stroma, but not in the tumour cells, proved to be excellent prognosticators both in all
stages and in early stage cases. Among early stages, when stromal TNC was negative, the 5-year survival rate was 88%.
Correspondingly, when FN was negative, no cancer deaths were observed. Five-year survival rates for abundant expression of
TNC and FN were 43% and 25%, respectively.
Conclusions: Stromal TNC and, especially, FN expressions differentiate patients into low- and high-risk groups. Surgery alone of
early stage primary tumours might be adequate when stromal FN is negative. Aggressive treatments should be considered when
both TNC and FN are abundant.
*Correspondence: Dr E Sundquist; E-mail: elias.sundquist@oulu.fi
Received 12 September 2016; revised 18 November 2016; accepted 20 December 2016; published online 17 January 2017
& 2017 Cancer Research UK. All rights reserved 0007 – 0920/17
FULL PAPER
Keywords: tongue cancer; prognosis; mesenchymal stromal cell; tenascin-C; fibronectin; stroma; immunohistochemistry; tumour
microenvironment
British Journal of Cancer (2017) 116, 640–648 | doi: 10.1038/bjc.2016.455
640 www.bjcancer.com | DOI:10.1038/bjc.2016.455
Globally an estimated 405 000 new cases of oral cancer are
diagnosed annually, of which about 50% are located in the oral/
mobile tongue. Oral tongue squamous cell carcinoma (OTSCC) is
an aggressive subset of the oral squamous cell carcinomas (OSCCs)
with the highest invasion and metastasis properties (Bello et al,
2011; Ganly et al, 2012; Kim and Cha, 2012). Lymph node
metastases are the single most important prognostic factor of
OSCC. However, in early stage cancers, lymph node metastases are
often occult without preoperative signs (Bello et al, 2010). The
prognosis can be improved by performing elective neck dissection
for all early stage OTSCC patients (D’Cruz et al, 2015), but most of
the patients do not benefit from elective neck dissection, from
which surgery-related morbidities are substantial (Kelner et al,
2015). Owing to the lack of prognostic markers, the mortality of
early stage (cT1-T2N0) OTSCC is still comparatively high (Ganly
et al, 2012), as patients with aggressive OTSCC are not recognised.
Thus the development of reliable methods to detect aggressive
early stage tumours is essential in order to provide treatment with
the most efficient modalities.
The role of the tumour microenvironment (TME) in cancer
development has become abundantly clear. The fibroblasts and
extracellular matrix (ECM) components are crucial for the
proliferation and invasion of cancer cells through dynamic
interactions between cancer cells and ECM molecules (Metwaly
et al, 2012). As mesenchymal stem cells, among other TME
components, are known to enhance the invasion of OTSCC cells
(Sobral et al, 2011; Salo et al, 2013), we used intact human
mesenchymal stromal cells (hMSCs) as an immunising agent to
produce specific antibodies in mice. The aim of this study was to
characterise novel monoclonal mouse antibodies produced against
hMSCs, and to evaluate the prognostic value of two of the target
antigens – tenascin-C (TNC) and fibronectin (FN) – in OTSCCs
according to the reporting recommendations for tumour marker
prognostic studies (REMARK) criteria.
MATERIALS AND METHODS
New anti-TNC and anti-FN antibodies. Mice (C57BL/6) were
immunised using cultured live hMSCs as single-cell suspensions in
PBS (i.p). The hMSCs were obtained from bone marrow (BM) of
volunteer donors (two 16-year-old donors with arthritis) following
written consent approved by the Ethical Committee of the Northern
Ostrobothnia Hospital District, Oulu, Finland. Bone marrow hMSC
isolation and culture followed the protocol described by Leskelä et al
(2003). The presence of both MSC-positive (CD73, CD90 and
CD105) and MSC-negative (CD14, CD19, CD34, CD45 and HLA-
DR) cell surface markers of the cultured cells were assayed by flow
cytometry, and the differentiation potential of isolated cells was
assessed for adipogenic and osteogenic differentiation capability (data
not shown). The preparation of the live cells and the booster
immunisation was performed twice. On the basis of the antibody
titres, mice were chosen and their spleens prepared for fusion. Positive
hybridomas were subcloned several times using standard limiting
dilution procedures.
Media from hybridoma lines were screened against several cell
types by cyto-ELISA (Grunow et al, 1994), flow cytometry and
western blot. The monoclonal antibodies produced by the
hybridoma lines were isolated using protein G. The target antigens
were isolated from cultured hMSC cell homogenate by immuno-
precipitation with the purified antibody covalently coupled to the
surface of Dynabeads (M270, Invitrogen, Carlsbad, CA, USA) or
using Protein G resin (Sigma-Aldrich, Ayshire, UK). The immuno-
isolated target molecules were separated using SDS-7.5% PAGE.
The bands from protein gels (Figure 1A and B) were identified
using peptide fingerprinting (trypsin cleavage and MS Maldi TOF
analysis of proteolytic fragments) and Mascot Database search
(Matrix Science, London, UK).
Purified antibodies were assayed for immunofluorescence using
the Dylight 550 conjugated anti-mouse secondary antibody and
DAPI. The formalin fixed, paraffin-embedded synovial tissues were
also assayed with the new antibodies (Figure 1C). The negative
control was stained with the idiotype antibody (unrelated mouse
IgG1). For western blots of various cell types and tissues, the
samples were incubated with the new matrix antibodies at a
concentration of 1mg ml 1 for 2 h and, after washing, the bound
antibodies were detected with peroxidase conjugated anti-mouse
antibody (Sigma-Aldrich). Target antigen for antibodies from two
clones (A8 and D2) was identified as human TNC and target antigen
for antibodies from three clones (F12, C1 and B6) was identified as
human FN. From these antibodies, the ones from clones D2 for
TNC and F12 for FN were chosen to be used in this study.
Patients and biological material. This retrospective multi-centre


































Figure 1. Characterisation of the new matrix antibodies. Coomassie-
stained SDS-7.5% PAGE of the target antigens from the cultured hMSC
lysate immunoprecipitated using the new anti-tenascin-C monoclonal
antibody D2 (A) or anti-fibronectin monoclonal antibody F12 (B).
Molecular weight markers are shown on the left of the gels: Bio-Rad
Dual Colour (A) and Sigma Colorburst (B). The identified target antigen
is marked with arrows. Bands migrating at B60 kDa region are mouse
antibody fragments detached from the resin (A). The immunostaining
of the synovia tissue sections with anti-tenascin-C D2, anti-fibronectin
F12 and idiotype IgG1 as negative control (C). New antibodies were
compared with commercial ones by staining representative samples
from ‘negative’ and ‘abundant’ groups using both D2 and commercial
DB7 for TNC (D), and both F12 and commercial NCL-FIB for FN (E).
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of Oulu (OUH, n¼ 107) and Kuopio (KUH, n¼ 21) in Finland
from 1979 to 2009, and UOPECCAN Cancer Hospital (n¼ 27) and
Oncology Center of Cascavel (CEONC, n¼ 23) in Brazil from 1998
to 2008. Of these 178 patients, 98 had been diagnosed with clinical
stage I (cT1N0M0) or II (cT2N0M0) OTSCC. The inclusion
criteria were sufficient clinical data and histological samples to
perform the analysis. All patients had undergone primary resection
of the tumour. Detailed patient demographic data of the early stage
patients are shown in Table 1, and demographic data of the pooled
group of all stage patients are in Supplementary Table 1. This study
was approved by the Ethical Committee of the Northern
Ostrobothnia Hospital District, Finland and the Finnish National
Supervisory Authority for Welfare and Health. In Brazil, this study
was approved by the Ethics Committee in Research of the
Piracicaba Dental School, University of Campinas (approval
number 100/2012).
Immunohistochemistry
TNC and FN. After characterisation, our novel TNC antibody D2
was qualitatively compared with the well-tested commercial
monoclonal TNC antibody DB7 (order #610003, Biohit, Helsinki,
Finland), and our FN antibody F12 was compared with the
commercial monoclonal antibody NCL-FIB (NCL-FIB, Leica
Biosystems, Newcastle, UK; Figure 1D and E). Representative
OTSCC samples from negative and abundant groups were stained
with both D2 and DB7, as well as F12 and NCL-FIB. Paraffin-
embedded resected tumours were obtained and prepared for
immunohistochemistry. In essence, 5 mm thick slices were
mounted on microscope slides and dewaxed in xylene. For epitope
retrieval, the sections were then heated in a microwave oven in
Tris-EDTA solution (pH 9) for 10 min and allowed to cool at room
temperature (RT) for 20 min. Endogenous peroxidase activity was
blocked using peroxidase-blocking solution (DAKO, Glostrup,
Denmark) for 10 min. The sections were then incubated with
primary antibodies at a dilution of 1 : 500 for 60 min at RT. For
visualisation, horseradish peroxidase (HRP)-conjugated antibodies
(DAKO) were introduced to sections for 10 min, after which
DAB chromogen was used for 5 min, and the sections were then
counterstained using Mayer’s haematoxylin.
a-Smooth muscle actin. A group of 60 randomly selected OTSCC
samples were stained for a-smooth muscle actin (a-SMA). The
sections were incubated with primary antibody (Dako monoclonal
mouse anti-human, 1 : 500, clone 1A4, M0851) for 30 min in RT.
Analysis of TNC and FN in the stroma and tumour cells.
Stromal TNC and FN stain was scored as previously described for
a-SMA (Bello et al, 2011), using a scale from 0 to 4 as follows:
0¼ no extracellular staining; 1¼ staining of individual confined
spots; 2¼ staining not confined to specific spots, more diffuse;
3¼ staining throughout the invasive front, distinguishable border
between the stained ECM and carcinoma cells; 4¼ staining
throughout the invasive front, no distinguishable border between
the stained ECM and carcinoma cells. For statistical analysis the
grade 0 was labelled as ‘negative’ (Figure 2A and E), grades 1–3
were merged into the ‘moderate’ group (Figure 2B and F) and
Table 1. Patient data of stage I and II OTSCC patients
N (%) All patients (n¼98) OUH (n¼59) KUH (n¼14) UOPECCAN (n¼8) CEONC (n¼17)
Patient data, stages I–II
Gender
Male 53 (54) 24 (41) 9 (64) 6 (75) 14 (82)
Female 45 (46) 35 (59) 5 (36) 2 (25) 3 (18)
Age at diagnosis
p55 26 (26) 13 (22) 3 (21) 3 (38) 7 (41)
56–69 33 (34) 15 (25) 7 (50) 4 (50) 7 (41)
X70 39 (40) 31 (53) 4 (29) 1 (12) 3 (18)
Range 32–99 32–99 33–80 45–77 40–80
Mean 64.18 67.17 62.29 56.50 59
Median 64 70 63.5 57 59
Follow-up time
Range 1–298 1–298 3–175 6–127 1–139
Mean 73.65 80.75 72.71 61.38 55.59
Median 57 64 60 47.5 51
Cause of death
Alive 49 (50) 31 (53) 6 (43) 5 (62) 7 (41)
Cancer 22 (22) 8 (14) 3 (21) 3 (38) 8 (47)
Other 27 (28) 20 (33) 5 (36) – 2 (12)
Grade
1 28 (28) 24 (41) 4 (29) – –
2 37 (38) 32 (54) 5 (36) – –
3 6 (6) 3 (5) 3 (21) – –
Missing 27 (28) – 2 (14) 8 (100) 17 (100)
Neck lymph nodes
Positive 2 (2) 2 (3) – – –
Negative 96 (98) 57 (97) 14 (100) 8 (100) 17 (100)
Adjuvant therapy
No 67 (69) 47 (80) 7 (50) 3 (37) 10 (59)
Radiotherapy 22 (22) 9 (15) 7 (50) 2 (26) 4 (23)
Radio- and chemotherapy 7 (7) 1 (2) – 3 (37) 3 (18)
Missing 2 (2) 2 (3) – – –
Recurrence
Yes 39 (40) 17 (29) 8 (57) 5 (62) 9 (53)
No 59 (60) 42 (71) 6 (43) 3 (38) 8 (47)
Abbreviations: CEONC¼Oncology Center of Cascavel; KUH¼Kuopio University Hospital; OTSCC¼oral tongue squamous cell carcinoma; OUH¼Oulu University Hospital. Data as
combination from all the hospitals, as well as separately from each hospital.
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grade 4 was labelled as ‘abundant’ (Figure 2C and G). If the same
tumour had areas of different staining intensity, the tumour was
scored according to the most severe grade.
Expression in the carcinoma cells was scored as follows: 0¼ no
cells with intracellular staining; 1¼ individual cells with intracel-
lular staining and 2¼ groups of cells with intracellular staining. For
statistical analysis, groups 1 and 2 were merged into a ‘positive’
group (Figure 2D and H). Scoring was performed by two of the
authors (ES or RM and JHK) independently and unaware of the
clinical outcome at the time of the analysis. Discrepancies in the
scoring were settled by an experienced oral pathologist (TS). Most
of the discrepancies were related to scores 1–3; scores which were
combined to the same group for statistical analyses. There were a
total of 44 cases that were scored differently by the assessors due to
stromal TNC in the pooled data of all the stages of disease. Of these
cases, 17 would have been included in different groups.
Furthermore, in 9 cases one of the assessors scored the sample as
negative and the other one as ‘not-negative’. The respective
numbers of cases for stromal FN scoring were 37, 16 and 8. Among
early stage cases, the numbers were 25, 8 and 5 for TNC and 21, 8
and 6 for FN.
Statistical analysis. Survival curves were created using the
Kaplan–Meier method with disease-specific death as the end
point, and death by other cause and end of follow-up as censoring
events. Differences between the groups were analysed by a log-rank
test.
The prognosis of the patients related to stromal and intracellular
TNC, and FN were evaluated by univariate analysis using the Cox
proportional hazard model. Differences between the groups were
evaluated using a w2-test.
Multivariate analysis was conducted using the Cox proportional
hazard model. In multivariate analysis the results were adjusted for
age, gender, adjuvant therapy and hospital, as well as stage among
the pooled group including all the stages. As there were no end
points (cancer deaths) in the FN-negative group among patients
with stage I–II OTSCC, no hazard ratios (HRs) could be calculated
in reference to this group. Hence, HRs for stromal FN in the stage
I–II patient group were calculated comparing ‘abundant’ with
‘moderate’.
Correlations between stromal TNC, FN and a-SMA were
calculated using a Spearman’s correlation test and 2-tailed
significance was applied. Kappa values for inter-rater agreement
in TNC and FN scoring was performed by cross tabulation and
statistical significance confirmed using a w2-test. Cross tabulation
was used for the analysis of association between clinical parameters
and stromal TNC and FN staining.
In all the analyses P-values p0.05 were considered statistically





























Figure 2. Scoring of stromal and intracellular TNC and FN. Stromal
TNC (A–C) and FN (E–G) were scored from 0 to 4 and grade 0 was labelled
‘negative’ (A and E), grades 1–3 were combined and labelled ‘moderate’
(B and F) and grade 4 was labelled ‘abundant’ (C and G). Intracellular
TNC (D) and FN (H) were scored from 0 to 2. Grade 0 was labelled
‘negative’ and 1–2 were combined and labelled ‘positive’ (D and H).
Table 2. Results of scoring of stromal and intracellular TNC, and FN of stage I and II OTSCC patients
N (%) All patients (n¼98) OUH (n¼59) KUH (n¼14) UOPECCAN (n¼8) CEONC (n¼17)
Frequencies of TNC and FN scores in different hospitals, stages I–II
Stromal TNC
Negative 26 (27) 20 (34) – 2 (25) 4 (23)
Moderate 65 (66) 35 (59) 11 (79) 6 (75) 13 (77)
Abundant 7 (7) 4 (7) 3 (21) – –
Cellular TNC
Negative 60 (61) 32 (54) 12 (86) 4 (50) 12 (71)
Positive 38 (39) 27 (46) 2 (14) 4 (50) 5 (29)
Stromal FN
Negative 35 (36) 27 (46) 3 (21) 1 (13) 4 (24)
Moderate 55 (56) 28 (47) 10 (72) 6 (74) 11 (64)
Abundant 8 (8) 4 (7) 1 (7) 1 (13) 2 (12)
Cellular FN
Negative 63 (64) 47 (80) 7 (50) 4 (50) 5 (29)
Positive 35 (36) 12 (20) 7 (50) 4 (50) 12 (71)
Abbreviations: CEONC¼Oncology Center of Cascavel; FN¼ fibronectin; KUH¼Kuopio University Hospital; OTSCC¼oral tongue squamous cell carcinoma; OUH¼Oulu University Hospital;
TNC¼ tenascin-C. Amounts of various scoring groups shown in total and for each individual hospital separately.
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OriginPro 2015 (OriginLab, Northampton, MA, USA) or SPSS
(IBM Corp. Released 2013. IBM SPSS Statistics for Windows,
Version 22.0. Armonk, NY, USA: IBM Corp.).
RESULTS
Immunohistochemical validation of tenascin-C and fibronectin
antibodies. The immunisation of mice with live BM hMSCs
resulted in a series of antibodies (anti-CD73, chondroitin sulphate
proteoglycan, FN, TNC, type VI collagen and CD13). However,
after testing these in paraffin-embedded OTSCC tissue sections,
the FN and TNC gave the most specific and strongest staining
signals. Two of the clones were characterised as clones of anti-TNC
and three as anti-FN, respectively. One clone of each (D2 for TNC
and F12 for FN) was selected to be used in immunohistochemistry.
When we compared our novel antibodies with commercially
available antibodies, the staining patterns were similar in all of the
tested samples (Figure 1D and E) and met the same scoring
criteria. However, less unspecific staining was detected in the
samples stained with D2 in comparison with DB7 (Figure 1D). The
number of cases in each staining group from each of the hospitals
is indicated in Table 2 for early stages and in Supplementary
Table 2 for all stages. In early stage samples, the concordance for
TNC and FN staining was high (kappa 0.827 for TNC and kappa
0.849 for FN, Supplementary Table 2).
Stromal TNC predicts outcome in OTSCC. The expression
patterns of TNC were variable when comparing the stromal
fibroblast-like cell and cancer cell components of the tumours.
Stromal TNC expression was not associated with any of the clinical
and demographic parameters (gender, age, hospital, stage, neck
lymph nodes and adjuvant therapy, Supplementary Tables 3 and
4). A total of 65 cancer deaths occurred among combined group of
all the stages including 178 patients during the whole follow-up
period.
In the pooled group (all stages of disease), abundant stromal
TNC served as a prognosticator in univariate analysis when
compared with the negative group, with a HR and 95%
confidence intervals (CI) of 3.21 (1.48–6.96; Supplementary
Table 5). Five-year cumulative survival rates were 70%, 70% and
20% for the negative, moderate and abundant groups, respectively
(Supplementary Figure 1A and E). The numbers of cancer
deaths/total number of patients in a given group during the whole
follow-up time in the negative, moderate and abundant groups
were 14 out of 43, 39 out of 119 and 12 out of 16, respectively.
When compared with the stromal TNC-negative group, the age,
gender, hospital, adjuvant therapy and stage-adjusted HR and 95%
CI in the multivariate analysis for abundant group was 2.48
(1.04–5.90). Tenascin-C expression in the tumour cells did not
have statistically significant prognostic value (Supplementary
Figure 1C and Supplementary Table 5).
Stromal and intracellular FN predict outcome in OTSCC. The
stromal expression of FN in fibroblasts and the fibrillary network
was associated with hospital, stage, lymph node metastasis and
treatment modalities in the combined group of all stages
(Supplementary Table 3). Among stages I–II, the stromal
expression of FN was associated only with adjuvant therapy
(Supplementary Table 4).
In the pooled group (all stages of disease), stromal FN
was an excellent prognosticator (Supplementary Figure 1B and
Supplementary Table 5) with 5-year cumulative survival rates
being 89%, 62% and 22% for the negative, moderate and abundant
groups, respectively (Supplementary Figure 1E). The number of
cancer deaths/total number of patients during the whole follow-up
time in the negative, moderate and abundant groups was 5 out of
51, 43 out of 105 and 17 out of 22, respectively. In this pooled
group, intracellular FN expression also predicted a poor prognosis
(Supplementary Figure 1D and Supplementary Table 5) with a
5-year cumulative survival rate of 75% for the negative group and
54% for the positive group (Supplementary Figure 1E). In the
univariate analysis including all stages, HRs for moderate
and abundant stromal FN were 5.45 (2.16–13.77) and 13.58
(4.97–37.11), respectively (Supplementary Table 5). The HR for
FN-positive cancer cells was 2.06 (1.25–3.38). In multivariate
analysis the respective HRs were 5.33 (2.07–13.73) and 9.64
(3.34–27.83), and 2.08 (1.22–3.56) for FN-positive cancer cells
(Supplementary Table 5).
Subgroup analysis of TNC and FN stainings. As staining
patterns of both TNC and FN were strongly associated with
patient outcome, we did a subgroup analysis in early stage OSTCC
patients. Among early stage patients, there were a total of 22 events
for 98 patients during the whole follow-up period.
There was no difference in outcome observed between stromal
TNC-negative and moderate groups (Figure 3A and E) or between
cellular TNC-negative and positive groups (Figure 3C and E)
among early stage patients. However, the group with abundant
stromal TNC differed significantly from those with negative or
moderate staining with a 5-year survival of 43% (in comparison
with 88% for negative and 82% for the moderate groups). The HRs
were 5.18 (1.29–18.61) and 6.54 (1.20–35.75) in uni- and
multivariate analyses in comparison with the negative group,
respectively (Table 3). The number of cancer deaths during the
whole follow-up time in the negative, moderate and abundant
groups was 5 out of 26, 13 out of 65 and 4 out of 7, respectively.
Cancer cell TNC expression had no statistically significant
prognostic value (Figure 3C and E and Table 3).
Surprisingly, no cancer deaths of early stage patients were
observed when stromal FN was negative. Thus, all of the cancer-
specific deaths occurred in the moderately or abundantly stained
groups. The numbers of cancer deaths during the whole follow-up
time in the negative, moderate and abundant groups were 0 out of
35, 15 out of 55 and 7 out of 8, respectively. The 5-year cumulative
survival rates were 100%, 76% and 25% for the negative, moderate
and abundant groups, respectively (Figure 3B and E). As there were
no disease-specific deaths in the stromal FN-negative group, the
HR for the abundant group was calculated by comparing it with
the moderate group. This resulted in HRs of 6.10 (2.36–15.75) and
5.91 (1.75–19.94) in uni- and multivariate analyses, respectively
(Table 3).
Intracellular FN proved to be a significant prognostic factor in
early stage cases in Kaplan–Meier analysis, but not in Cox
regression uni- or multivariate analysis with cumulative 5-year
survival rates of 85% and 72% for negative and positive groups,
respectively (Figure 3D and E; Table 3).
Correlations of stromal TNC, FN and a-SMA. Carcinoma-
associated fibroblasts (CAFs), which are identified by their
intracellular a-SMA, are known predictors for poor prognosis in
various malignancies (de Vlieghere et al, 2015), including OTSCC
(Kellermann et al, 2007; Li et al, 2015; Bagordagis et al, 2016).
However, CAFs are not prognostic indicators at early stage OTSCC
(Almangush et al, 2014; Kelner et al, 2015), only in patient material
of pooled stages, and at late stages when the variation in prognostic
markers does not affect the choice of treatment so drastically, as
more effective modalities are utilised in all cases. In this study we
re-evaluated the prognostic significance of stromal a-SMA using a
pilot group of 60 (with 17 cancer deaths) random samples from
our extensive patient material. Indeed, in concordance to previous
work of Almangush et al (2014) and Kelner et al (2015), in our
pilot group the stromal a-SMA was found not to be predictive of
patient outcome in early stage cases (Supplementary Figure 2). In
addition, among early stage cases only a weak correlation was
found between stromal a-SMA and TNC (0.395; 0.344 in all stages)
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or FN (0.441; 0.402 in all stages, Supplementary Table 2), the two
proteins shown in this study to have prognostic value in early stage
OTSCC. Furthermore, a correlation was found in early stage cases
between stromal TNC and FN with a correlation coefficient of
0.612 (0.617 in all stages, Supplementary Table 2).
After we found a strong correlation between stromal TNC and
FN, we analysed those cases in which abundant staining of both
these markers was observed in the stroma. A total of 14 patients
showed abundant staining of both stromal TNC and FN, and 5 of
these were among early stage OTSCC. Remarkably, among all
stages there was only 1 patient alive after follow-up; 12 deaths were
due to cancer and 1 due to another cause. There were no survivors
at follow-up among the early stage patients; four were cancer
deaths and one due to another cause.
DISCUSSION
There is a lack of potential markers to assess the need of elective
neck dissection for early stage tongue cancer. In this international
multi-centre study, we show that immunohistochemical staining
for FN and TNC could potentially be used in clinical decision-
making for early stage OTSCC.
The strengths and limitations of our study should be taken into
account when interpreting the results. Our study had an
international, multi-centre study design, with which we aimed to
counteract country-specific biases. The sample size in early stage
group is small (n¼ 98), especially in TNC and FN abundant
groups, and might limit the statistical power and analyses in this
group. This can be seen in the wide CIs in some of the analyses.
However, the effects of TNC and FN expression were similar in
both early and late-stage cancers, suggesting actual effect for the
biomarkers. Finally, we adjusted for several pre-determined
confounding factors in our analyses and showed that TNC and
FN are associated to survival, also after the adjustment.
Although several OTSCC prognostic molecular markers have
been reported (Bello et al, 2010), so far none is in clinical use to
pinpoint those individuals who benefit from the primary neck
dissection and multimodality treatment (Barnes et al, 2005). In this
study, we hypothesised that the expression of two ECM proteins
could predict the prognosis of cancers. After mice immunisation
with stromal cells and production of related antibodies, we decided
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Figure 3. Survival of stage I and II OTSCC patients. Kaplan–Meier curves representing the cumulative survival of early stage OTSCC patients
divided by stromal TNC (A) and FN (B) staining, as well as cellular TNC (C) and FN (D). In curves A–D the survivals are shown throughout the entire
follow-up time. Five-year survivals are shown separately (E). Log-rank test was used to test statistical significance.
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OTSCC, as the role of these proteins as prognostic indicators in
several cancers is well known (Jahkola et al, 1999; Emoto et al,
2001; Ioachim et al, 2002; Brunner et al, 2004; Ioachim et al, 2005;
O’Shannessy et al, 2014). Neither of these proteins had been
previously studied for their ability to predict prognosis of early
stage OTSCC. In this study we showed that the identification of
patients in low-risk and high-risk groups could potentially be
achieved by assessing the stromal expression of TNC and FN.
Stromal TNC and FN were both independent prognostic indicators
not only in pooled stages of OTSCC, but most importantly in
cases with clinical stages I–II when abundant stromal staining is
detected.
Tenascin-C is an ECM glycoprotein with a six-armed
quaternary structure. Under physiological conditions, TNC is
found abundantly in several embryonic tissues, especially related
to the epithelial mesenchymal transition (EMT), and to cell
migration pathways. In adult tissues, it is expressed mainly during
inflammation, wound healing and cancer progression (Orend
and Chiquet-Ehrismann, 2006). Increased TNC expression in the
tumour-adjacent ECM has been shown to correlate with a clinically
aggressive phenotype or poor prognosis in several cancers such as
oesophageal (Yang et al, 2016), breast (Ishihara et al, 1995; Jahkola
et al, 1998) colorectal (Emoto et al, 2001; Sis et al, 2004), bladder
(Brunner et al, 2004) and Merkel cell carcinomas (Koljonen et al,
2005); glioma (Herold-Mende et al, 2002), malignant pleural
mesothelioma (Kaarteenaho-Wiik et al, 2003), glioblastoma multi-
forme (Leins et al, 2003), malignant melanoma (Kääriäinen et al,
2006) and astrocytoma (Varga et al, 2012). In OSCC, TNC is
produced by carcinoma cells (Driemel et al, 2007) or by
surrounding mesenchymal fibroblast-like cells (Hindermann
et al, 1999; Metwaly et al, 2012). Tenascin-C is present in the
stroma of potentially malignant oral lesions and its expression is
increased along the degree of dysplasia (Tiitta et al, 1994).
Furthermore, TNC expression is high in budding cancer cells and
in the surrounding stroma (Tiitta et al, 1994; Hindermann et al,
1999). Tenascin-C has a variety of pro-tumourigenic interactions
with cancer cells, CAFs, lymphocytes and tumour-associated
macrophages, as well as angiogenesis promoting interactions with
endothelial cells. It interacts with cancer cells by reducing
adhesion, enhancing proliferation, migration and invasion, and
increasing dissemination and homing. Tenascin-C inhibits adhe-
sion of CAFs, and activation, proliferation and cytokine production
of tumour infiltrating lymphocytes (Midwood and Orend, 2009).
Increased expression of TNC by carcinoma cells correlates with the
grade of OSCC (Hindermann et al, 1999). In our study, TNC
expression in tumour cells was not a prognosticator in early stage
OTSCC, nor was it a prognosticator among all the stages. On the
other hand, the results of the present study indicate that stromal
TNC was an independent prognosticator among all stages, and
more importantly, among early stages. However, TNC predicted
poor prognosis only when detected abundantly in the tumour
stroma as there was no difference in prognosis between negative
and moderate stromal TNC staining. Taken together, we
hypothesise that TNC is related to dissemination of cancer cells
and aiding metastasis formation leading to poor prognosis.
Fibronectin is a multifunctional glycoprotein organised in a
fibrillary network. It is expressed mainly by fibroblasts, and during
development and wound healing. Fibronectin regulates a variety of
cell activities such as adhesion, migration, growth and differentia-
tion (Mao and Schwarzbauer, 2005; White et al, 2008) and is
involved in cancer invasion and metastasis (Stivarou and
Patsavoudi, 2015), and stromal FN correlates with poor prognosis
or aggressive phenotypes in colorectal cancer (O’Shannessy et al,
2014), urothelial carcinoma (Ioachim et al, 2005) and breast cancer
(Ioachim et al, 2002). Fibronectin is one of the markers of EMT, a
process essential for dissemination and invasion of carcinoma
cells (Chong et al, 2012), as well as one of the markers of
angiogenesis in primary tumours and metastases (Rybak et al,
2007). Fibronectin is upregulated in head and neck cancer (Al
Moustafa et al, 2002; Ferrari et al, 2009), and the presence and
amount of FN in tumour stroma is linked to an increased number
of cervical metastases, extracapsular spread and elevated risk for
disease-specific mortality in OSCCs (Lyons et al, 2001). Here, in
concordance to previous studies, stromal FN was shown to be an
excellent prognosticator among all stages of OTSCC and more
importantly among early stage cases. The fact that there were no
disease-specific deaths in the stromal FN-negative group among
stage I–II patients is itself a remarkable demonstration of the
specific nature of this marker. Cellular FN, on the other hand, had
prognostic value in the pooled group of all stages in univariate
analysis, and additionally it was an independent prognosticator in
multivariate analysis. Furthermore, cellular FN predicted survival
in stages I–II in Kaplan–Meier, but not in Cox regression uni- or
multivariate analysis.
Fibronectin and TNC are co-expressed in several cancers
(Hanamura et al, 1997; Yoshida et al, 1997) including OSCC
(Ramos et al, 1998) and play a role in the healing by influencing
cell adherence and migration especially in epithelial cells
(Mackie et al, 1988). It has been suggested that both TNC and
FN, as antagonists for each other (TNC being an anti-adhesive and
FN an adhesive protein), are essential in cancer invasion (Yoshida
et al, 1997). In support of this, Ramos et al (1998) found that TNC
matrix production was blocked in vitro when FN antibody was
introduced to CAF monolayer culture cultivated on FN-coated
Table 3. Cox regression uni- and multivariate analyses of
stage I and II OTSCC patients
HR 95% CI for HR P-value
Univariate analysis, stages I–II
Stromal TNC 0.025
Negative 1
Moderate 1.09 0.39–3.07 NS
Abundant 5.18 1.29–18.61 0.019
Cancer cell TNC NS
Negative 1
Positive 1.03 0.43–2.48 NS
Stromal FNa o0.001
Moderate 1
Abundant 6.10 2.36–15.75 o0.001
Cancer cell FN NS
Negative 1
Positive 2.30 0.99–5.33 NS




Abundant 6.54 0.23–2.48 0.030
Cancer cell TNC NS
Negative 1
Positive 1.61 0.54–4.78 NS
Stromal FNa 0.004
Moderate 1
Abundant 5.91 1.75–19.94 0.004
Cancer cell FN NS
Negative 1
Positive 1.56 0.61–4.04 NS
Abbreviations: CI¼ confidence interval; FN¼ fibronectin; HR¼hazard ratio; OTSCC¼
Oncology Center of Cascavel; TNC¼ tenascin-C. Multivariate analysis adjusted for age,
gender and hospital. HR and their 95% CI, as well as P-values. Analyses were performed
separately for stromal and cellular TNC and FN. In multivariate analysis the HRs were
adjusted for age, gender and hospital. The HR for stromal FN in multivariate analysis was
calculated by comparing abundant to moderate due to the lack of end points (cancer
deaths) in the FN-negative group. Statistically significant values are bolded.
aHR could not be calculated comparing with ‘Negative’ group due to lack of end points in
that group.
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glass coverslips. This hypothesis is supported by our results as well,
as we observed a strong correlation between stromal TNC and FN
in our clinical sample (Supplementary Table 2). Furthermore,
additional prognostic value was observed in our cohort among
those cases with abundant stromal TNC and FN; among all the
stages only one patient survived and no patients among the early
stages survived. This implies a strong biological synergy of these
proteins in cancer progression.
Our results provide feasible tools for more accurate division of
the early stage OTSCC patients into low-risk and high-risk groups.
These could be utilised in clinical decision-making in terms of
primary neck dissection and multimodality treatments. Further-
more, our results should encourage more basic research on the
biology of cancer/TME-interactions, and demonstrate the transla-
tional relevance of research on specific proteins. Even though our
results provide a basis for using TNC and FN in routine pathology
to categorise early stage OTSCC patients into low- and high-risk
groups, the cohort was relatively small (n¼ 98 for early stage
patients). The small number of patients led to relatively broad CIs
in Cox regression analysis, especially in abundant stromal FN and
TNC among early stage patients. Although we successfully
compared our antibodies with commercial ones, these studies
should be replicated using other antibodies for TNC and FN, and
preferably with larger patient groups.
In conclusion, based on our multi-centre study we recommend
the analysis of stromal TNC and FN as an integral part of diagnosis
and treatment planning in early stage OTSCC. When stromal TNC
and FN both turn out to be negative, elective neck dissection
and multimodality treatments should be avoided, whereas
abundant stromal staining of these proteins provides a strong
signal to consider more aggressive treatments. If future studies
demonstrate that immunohistochemical staining of TNC and FN
assessed from biopsies is equally specific in the prognostication to
that of surgical specimens, the treatment regimen can be chosen
preoperatively.
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